J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270009332813v1
49/6/684    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yau, W.-P.
Right arrow Articles by Chan, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yau, W.-P.
Right arrow Articles by Chan, E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

DRUG INTERACTIONS

Mechanism-Based Enterohepatic Circulation Model of Mycophenolic Acid and Its Glucuronide Metabolite: Assessment of Impact of Cyclosporine Dose in Asian Renal Transplant Patients

Wai-Ping Yau, PhD, Anantharaman Vathsala, MD, FRCP, Huei-Xin Lou, PharmD, Shufeng Zhou, PhD and Eli Chan, PhD

From the Department of Pharmacy, Faculty of Science, National University of Singapore (Dr Yau, Dr Chan); Department of Renal Medicine (Dr Vathsala) and Department of Pharmacy (Dr Lou), Singapore General Hospital, Singapore; and School of Health Sciences, RMIT University, Victoria, Australia (Dr Zhou).

Mycophenolic acid (MPA) is mainly metabolized to MPA-glucuronide (MPAG), which may be reconverted to MPA following enterohepatic circulation (EHC). A physiologically realistic EHC model was proposed to estimate and assess the impact of cyclosporine (CsA) dose on the extent of EHC of MPA and MPAG. After the first oral dose of mycophenolate mofetil (MMF), the MPA and MPAG plasma concentration-time data of 14 adult renal transplant patients (12 receiving concomitant CsA and prednisolone and 2 receiving only concomitant prednisolone without CsA) were analyzed by individual pharmacokinetic modeling using a proposed 5-compartment drug and metabolite EHC model with a time-varying gallbladder emptying process. Simulations were performed to assess the influence of the time of bile release after dosing (Tbile) and the gallbladder emptying interval ({tau}gall) on the EHC process. The extent of EHC for both MPA and MPAG tended to be lower in the group receiving CsA coadministration and decreased with increasing total body weight-adjusted CsA dose. Simulations revealed that Tbile and {tau}gall influenced the time of occurrence and maximum concentration of the second peak, as well as the extent of EHC, for MPA and MPAG.


Key Words: Mycophenolic acidpharmacokinetic modelingenterohepatic circulationrenal transplantcyclosporine

Address for reprints: Eli Chan, PhD, Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Republic of Singapore; e-mail: phaelic{at}nus.edu.sg.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J Clin PharmacolHome page
K. Rupprecht, C. Schmidt, A. Raspe, F. Schweda, M. Shipkova, W. Fischer, M. Bucher, F. Kees, and L. Faerber
Bioavailability of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium Is Differentially Affected by Pantoprazole in Healthy Volunteers
J. Clin. Pharmacol., October 1, 2009; 49(10): 1196 - 1201.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American College of Clinical Pharmacology